Evidence report library
Browse health and science claims by evidence strength.
Search deHype reports by topic, grade, study type and clinical relevance. Each card gives the practical verdict first, then links to the full source-chain review.
Explore by topic
Top public report topics, ranked by current archive coverage.
Latest evidence reports
Concise archive cards help readers decide whether to open the full source-chain report.
Evidence check: Copper drug clears toxic Alzheimer’s proteins and restores memory
Findings are promising but limited to laboratory mouse models; human benefit, safety, and effectiveness in Alzheimer’s are untested.
Evidence check: Dementia: Joint pain supplement may speed progression
The evidence for glucosamine accelerating dementia is preliminary, indirect, and partly observational; findings require replication and do not justify clinical changes at this stage.
Evidence check: Your nose could detect Alzheimer’s years before symptoms begin
The research offers scientific insight into early immune changes and olfactory loss in Alzheimer’s, but the article’s diagnostic and therapeutic framing exceeds the current clinical evidence.
Evidence check: Blood and spinal fluid proteins reveal distinct fingerprints of four brain diseases
This is a robust molecular profiling study in humans, but proposed diagnostic and therapeutic applications are not yet validated, making clinical conclusions premature.
Evidence check: Cycling Linked to Lower Risk of Dementia, Study of Half a Million Finds
The study shows an association between cycling and lower dementia risk, but is observational and does not establish that cycling prevents dementia; results could be affected by confounding factors.
Evidence check: Scientists Discover Brain Pathway That May Slow Parkinson’s Disease – but Only in Women
The article describes preliminary findings from mouse models that cannot yet be applied to humans or guide clinical care.
Evidence check: Scientists found a hidden Alzheimer’s trigger and shut it down
The research shows that targeting IDOL reduced amyloid plaques and improved certain neuronal features in animals, but there is no evidence yet for clinical effectiveness or safety in humans.